NicOx Reports Positive Data for Cholesterol Drug
NicOx announced that NCX 6560, its drug candidate for high cholesterol, met its primary and secondary endpoints in a Phase Ib man-in study.
NicOx announced that NCX 6560, its drug candidate for high cholesterol, met its primary and secondary endpoints in a Phase Ib man-in study.
A new analysis of AstraZeneca’s cholesterol-lowering statin Crestor shows that the drug sharply reduces the risk of venous thromboembolism (VTE), a potentially fatal disorder in which blood clots can form in the legs and travel to the lungs.
Copyright © 2024 | WordPress Theme by MH Themes